Close for now Do you hold SG, US, HK or MY stocks? How are you tracking them now?
View our Demo portfolio to learn how StocksCafe will do it for you intelligently!
Sign up for free now!

USX:STML - Stemline Therapeutics Inc (USD 11.55) Stemline Therapeutics Inc
Sector: Health Technology, Industry: Biotechnology

Add to WatchList

Set Alert


USD 11.55    +0.060 (+0.52%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

19 Feb 2019


Overview

19 Feb 2019

Day Change: 0.060 (0.52%)

52 Wk Range: 7.82 - 20.55

Day's Range: 11.41 - 11.84

Last Volume: 324,839

Current Yield: 0%

Open: USD 11.5

Close: USD 11.55

19 Feb 2019

Metric STML S.Median
Beta 1.61 0.75
VaR 47.89 19.82
E.Shortfall 98.49 27.71
Liquidity 472.75K 108.82K

Fundamental

19 Feb 2019

PE: -4.151

Market Cap: 332.6M

Price Over Book: 5.235

Price Over Sales: 370.34

Return On Assets: -99%

Return On Equity: -126.1%

NAV Over Price: [Friends Only]

Screener

[Members Only]

Sign up for free to access most features of StocksCafe

Scorer

[Members Only]

Sign up for free to access most features of StocksCafe

Description

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

General

CEO: Ivan Bergstein

Headquarters: NEW YORK

Employees: 29

Sector: Health Technology

Industry: Biotechnology

Useful Links
Homepage

Price Simulation

My Notes

You currently do not have notes about this stock.




Dividends Tax Rate
Tax Rate (%)

Min Commission (USD)


Past Transactions Add Transactions

You do not have past transactions for this stock.


Shared Portfolios Stats
All Shared Portfolios
0% holds STML (0/194)
0% recent buy involves STML (0/134)
0% recent sell involves STML (0/63)

*recent means in the last 14 days.


Similar Stocks Celldex Therapeutics Inc.

Ardelyx Inc

Oncolytics Biotech, Inc.

Kitov Pharma Ltd

Wave Life Sciences Ltd.